Clinical pharmacology

Sun BioPharma Announces Pause in Enrollment of Clinical Trial of SBP-101 for Patients with Pancreatic Cancer

Friday, April 3, 2020 - 9:46pm

MINNEAPOLIS, MN, April 03, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced it will pause enrollment in its ongoing clinical trial of SBP-101.

Key Points: 
  • MINNEAPOLIS, MN, April 03, 2020 (GLOBE NEWSWIRE) -- Sun BioPharma, Inc. (OTCQB: SNBP), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced it will pause enrollment in its ongoing clinical trial of SBP-101.
  • The COVID-19 pandemic has affected the conduct of clinical trials at our US and Australian sites.
  • Patients currently enrolled in the clinical trial will continue to be treated.
  • Sun BioPharmas development program is currently targeting pancreatic cancer; its initial product candidate is SBP-101 for the treatment of patients with metastatic pancreatic cancer.

2020 Cirrhosis Clinical Trials Overview by Trial Status & Phase, Sponsor Type, End Point Status, Region and Country - ResearchAndMarkets.com

Friday, April 3, 2020 - 6:02pm

The "Cirrhosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Cirrhosis Global Clinical Trials Review, H1, 2020" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This clinical trial report, Cirrhosis Global Clinical Trials Review H1, 2020 provides an overview of Cirrhosis Clinical trials scenario.
  • The report provides top line data relating to the clinical trials on Cirrhosis.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.

Know Your Health Care Rights: 6 Tips for California Consumers During the COVID-19 Pandemic

Thursday, April 2, 2020 - 9:08pm

LOS ANGELES, April 2, 2020 /PRNewswire/ --Consumer Watchdog released a "Know Your Rights"tip sheettoday outlining 6things consumers should knowabouttheirhealth care cost and access rights during the COVID-19 pandemic.

Key Points: 
  • LOS ANGELES, April 2, 2020 /PRNewswire/ --Consumer Watchdog released a "Know Your Rights"tip sheettoday outlining 6things consumers should knowabouttheirhealth care cost and access rights during the COVID-19 pandemic.
  • California consumers and patients should know theirlegalrights asCOVID-19 is expected to heavily tax the resources of the health care systemand may exceed capacity insome communities,potentially resulting inlimitations on access to care,according to the non-profitand non-partisanConsumer Watchdog.
  • "We encourage California patients to wash their hands, respect social distancing rules, and know your health care rights!"
  • To ensure continued access to prescription medications while promoting social distancing during the COVID-19 pandemic, health insurersmayrelaxrefillrestrictionson "maintenance" prescriptionsfor chronic conditions.

Fate Therapeutics Announces First Patient Treated in First-in-human Clinical Trial of FT596 and Provides Corporate Update

Thursday, April 2, 2020 - 9:45pm

We are pleased to have worked with the Masonic Cancer Center, University of Minnesota to treat the first patient with FT596, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.

Key Points: 
  • We are pleased to have worked with the Masonic Cancer Center, University of Minnesota to treat the first patient with FT596, said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics.
  • The COVID-19 pandemic presents unprecedented challenges for clinical trial conduct worldwide, and we anticipate there will be delays across our studies.
  • We are also working closely with our clinical sites and principal investigators so that we are well positioned to accelerate clinical trial execution when pressures on the health system ease.
  • In response to the global COVID-19 pandemic, the Company is providing a business update on the conduct of its operations.

NuCana Provides Update on Impact of COVID-19 on Clinical Studies

Thursday, April 2, 2020 - 9:01pm

EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the status of its ongoing clinical studies.

Key Points: 
  • EDINBURGH, United Kingdom, April 02, 2020 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ: NCNA) has been closely monitoring the potential impact of the COVID-19 pandemic on its operations and announced today an update on the status of its ongoing clinical studies.
  • In order to help to protect the health of patients and investigators at its clinical study sites, the enrollment of new patients in its ongoing clinical studies has been temporarily paused.
  • While NuCana continues to evaluate the impact of COVID-19 on its operations, the company believes that this pandemic will inevitably cause some delays to the timing of initiation and completion of its clinical studies.
  • However, the precise timing of delays and overall impact is currently unknown and NuCana is continuing to monitor the COVID-19 pandemic as it rapidly evolves.

AI Analysis Shows COVID-19 Widens Disparity in Medication Adherence Between Patient Populations

Thursday, April 2, 2020 - 1:47pm

NEW YORK, April 2, 2020 /PRNewswire/ --AllazoHealth, a healthcare technology company that uses artificial intelligence to make a positive impact on individual patient behavior, has released an analysis that shows a growing gap in medication adherence between patient groups since the COVID-19 pandemic arrived.

Key Points: 
  • NEW YORK, April 2, 2020 /PRNewswire/ --AllazoHealth, a healthcare technology company that uses artificial intelligence to make a positive impact on individual patient behavior, has released an analysis that shows a growing gap in medication adherence between patient groups since the COVID-19 pandemic arrived.
  • "Of particular significance is the change in percentage of patients who refill their prescriptions late.
  • Comparing late refill rates for patients who are at high-risk of non-adherence vs. low-risk patients reveals a widening gap after the pandemic arrived."
  • "Patient engagement can take many forms; for example, helping the patient sign up for a home delivery service or converting their next fill to a longer days-supply."

4G Clinical Announces Appointment of Industry Veteran Barry Moore as VP of Delivery

Thursday, April 2, 2020 - 1:02pm

WELLESLEY, Mass., April 2, 2020 /PRNewswire/ --4G Clinical, a cutting-edge randomization and trial supply management (RTSM) provider, announced today the appointment of industry veteran Barry Moore as VP of Delivery.

Key Points: 
  • WELLESLEY, Mass., April 2, 2020 /PRNewswire/ --4G Clinical, a cutting-edge randomization and trial supply management (RTSM) provider, announced today the appointment of industry veteran Barry Moore as VP of Delivery.
  • Barry Moore, former Head of Clinical Supply Solutions at GlaxoSmithKline (GSK), has over 20 years of experience managing clinical trial supply chain systems, processes and solutions.
  • "My passion has always been finding novel ways to execute and accelerate clinical trials by utilizing technology," says Barry Moore.
  • "We are thrilled to have such a dynamic and driven thought leader join 4G Clinical," says David Kelleher, CEO of 4G Clinical.

Accelerated Enrollment Solutions and Science 37 Collaborate to Provide Virtual Trial Access to Patients Globally

Thursday, April 2, 2020 - 2:00pm

These patients can instead participate in AES studies through Science 37s MetasiteTM, a hybrid clinical trial methodology that combines traditional site visits with remote trial capabilities, allowing patients located virtually anywhere to participate in a clinical trial.

Key Points: 
  • These patients can instead participate in AES studies through Science 37s MetasiteTM, a hybrid clinical trial methodology that combines traditional site visits with remote trial capabilities, allowing patients located virtually anywhere to participate in a clinical trial.
  • The collaboration also enables Science 37 to extend its investigator network by leveraging AES global research network.
  • Science 37 is already renowned for our ability to conduct fully decentralized trials in the United States, said David Coman, chief executive officer of Science 37.
  • Accelerated Enrollment Solutions is a business of PPD that offers sponsors and contract research organizations distinctive site conduct and patient access solutions.

Trxade Spotlighted in Publication Discussing Healthcare Challenge, Solution

Thursday, April 2, 2020 - 1:30pm

However, the pandemic has only exacerbated Americas real healthcare challenge affordable healthcare and prescription medicines.

Key Points: 
  • However, the pandemic has only exacerbated Americas real healthcare challenge affordable healthcare and prescription medicines.
  • The only sensible solution may be to marshal the forces of innovation and technology to improve and expand healthcare services, streamline operating expenses, expedite deliveries and mitigate runaway costs.
  • At the epicenter of a multibillion-dollar opportunity, Trxade Group Inc. (NASDAQ: MEDS) ( MEDS Profile ) is delivering on a unique business strategy that makes healthcare and prescriptions more accessible, affordable and convenient, delineating Trxade in a fractured, inefficient industry.
  • These risks and uncertainties could cause the company's actual results to differ materially from those indicated in the forward-looking statements.

Momenta Provides Corporate Update Amid COVID-19 Pandemic

Thursday, April 2, 2020 - 12:30pm

Update on Clinical Trial Activities:

Key Points: 
  • Update on Clinical Trial Activities:
    Momenta remains committed to its development programs, but recognizes the impact and risks imposed by COVID-19 on the global healthcare system.
  • Momenta continues to enroll lower dose cohorts in Part B of the ongoing trial, however most of the sites have suspended enrollment due to the COVID-19 pandemic.
  • Momenta is closely monitoring the evolving situation and expects to resume patient enrollment and initiate delayed studies when conditions permit.
  • Momenta has implemented measures to mitigate the spread of COVID-19 and protect the health and safety of its personnel amid this pandemic.